Rafael Holdings, Inc. (RFL): R&D Expense

Annual figures by period end, from SEC filings.

$24.33M
Year ended 2026-07-31
+56.8%
3-year compound annual growth
+37.7%
5-year compound annual growth
2018-07-31: $995.0K2019-07-31: $1.03M2020-07-31: $2.39M2021-07-31: $4.91M2022-07-31: $8.74M2023-07-31: $6.31M2024-07-31: $4.17M2025-07-31: $12.82M2026-07-31: $24.33M$24.33M
2018-07-31 R&D Expense (USD) 2026-07-31
Period endedR&D ExpenseChange YoYSource filing
2026-07-31$24.33M+89.8%2026-10-29, From 2025-08-01
2025-07-31$12.82M+207.5%2026-10-29, From 2024-08-01
2024-07-31$4.17M-33.9%2025-10-29, From 2023-08-01
2023-07-31$6.31M-27.8%2024-12-20, From 2022-08-01
2022-07-31$8.74M+78.2%2023-10-30, From 2021-08-01
2021-07-31$4.91M+105.2%2022-10-31, From 2020-08-01
2020-07-31$2.39M+132.8%2021-10-18, From 2019-08-01
2019-07-31$1.03M+3.2%2020-10-29, From 2018-08-01
2018-07-31$995.0Kn/a2019-10-04, From 2017-08-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Rafael Holdings, Inc. (RFL)2026-07-31$24.33M+89.8%
Rallybio Corp (RLYB)2025-12-31$19.60M-52.8%
Shattuck Labs, Inc. (STTK)2025-12-31$35.27M-47.5%
60 Degrees Pharmaceuticals, Inc. (SXTP)2025-12-31$2.11M-57.8%
Dare Bioscience, Inc. (DARE)2025-12-31$5.52M-61.4%
Lexaria Bioscience Corp. (LEXX)2025-08-31$8.24M+249.0%
Neuphoria Therapeutics Inc. (NEUP)2025-06-30$9.01M-4.4%
BioXcel Therapeutics, Inc. (BTAIQ)2025-12-31$30.25M-0.6%
Longeveron Inc. (LGVN)2025-12-31$12.04M+48.0%

Compare RFL, RLYB, STTK, SXTP side by side · Screen every company in Pharmaceutical Preparations ↗